Navigation Links
Suven Seeks Permission for Trials of New Drug

Hyderabad, July 12 (IANS) Suven Life Sciences has submitted an application with the Drug Controller General of India for permission to undertake phase-1 clinical trials of its new drug Suvn-502 for treatment of cognitive disorders such as Alzheimer's and schizophrenia.

'Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need and Suven's primary focus is to discover drugs that address significant unmet medical needs,' said a statement by the firm.

Suven is a Hyderabad-based life sciences company, which is involved in contract research and manufacturing services, drug discovery and development support services and collaborative research partner with global pharma majors.

Suven's research focuses on developing treatments for Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.


'"/>




Page: 1

Related medicine news :

1. Gujarat Seeks To Scale Down Infant Mortality Rate
2. Europe Seeks Indian Expertise
3. Book Seeks To Rehabilitate Soldiers
4. Government Seeks To Wipe Out Prostitution
5. Multiple Sclerosis Patient Seeks Help of Stem Cells
6. AIIMS Doctors Seeks Ramadoss Intervention For Venugopal’s Remova
7. Human Chain Seeks AIIMS Status For Tiruchi Medical College
8. Harney Seeks Approval for New Medical Practitioners Bill
9. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
10. BJP Seeks Tougher Laws Against Pre-Natal Sex Tests
11. Valiathan Committee Seeks Documents from AIIMS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... home care professionals, today announced that it has raised $1.675 M in seed ... , Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s ...
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... August 17, 2017 , ... Navigating ... a Florida-based oncology business advisor to oncology practices, announced today the results of ... of attributable savings from resolving critical clinical issues that would have otherwise resulted ...
(Date:8/16/2017)... , ... August 16, 2017 , ... An August 3rd article on Reuters ... subject of a report in JAMA (the Journal of the American Medical Association). The study ... able to achieve BMIs under 30, when compared to patients with lower BMIs. At present, ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology: